Century Therapeutics (IPSC) Keeps CNTY-813 IND on Track for 4Q 2026

Century Therapeutics (IPSC) announced that its CNTY-813 therapy is on track for IND submission in 4Q 2026, with clinical data expected in 2H 2027. The company also plans to initiate clinical trials for CNTY-308 in 2026. As of September 30, 2026, Century has $174.1 million in cash and investments, providing a runway into 1Q 2029. Joseph Truitt was appointed to the board.

Original reporting
Published Nov 12, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Century Therapeutics (IPSC) Keeps CNTY-813 IND on Track for 4Q 2026 — source image
Decision brief

The 30-second read

$CNTYBullishLow
01

Why it matters

The announced timelines reduce uncertainty around regulatory milestones, which may support the stock modestly.

02

Market read

Timeline confirmations are positive but lack immediate catalyst strength; likely limited short‑term price impact.

03

What to watch

Potential competition in iPSC therapies and regulatory scrutiny could affect future outcomes.

Relevance 6/10Novelty 6/10Timing: future outlook, no immediate trade trigger

Background

Century Therapeutics is a clinical‑stage biotech developing iPSC‑derived therapies for diabetes and CAR‑iT cell cancer treatments.

Company-level read

Ticker impact

$CNTYBullishMedium confidence
Context

Century Therapeutics announced its CNTY-813 IND submission remains on track for Q4 2026 and CNTY-308 trial start planned for 2026.

Expected impact

likely modest upside as investors price in reduced regulatory timing risk

Evidence & confidence

Timeline confirmations are favorable but no new data or financials were disclosed, limiting immediate price move.

Market effects

Adds confidence to the broader cell therapy and iPSC sector timeline expectations.

Limited to US biotech investors.

Minimal, as the news is company‑specific.

Counterpoint

The lack of concrete data may suggest delays; investors could remain cautious.

Key entities

  • Century Therapeutics

    US‑listed biotech (NASDAQ:CNTY) developing CNTY-813 and CNTY-308 programs.

Related articles

$CNTYMed

Century Casinos Considers Selling Alberta Assets

Century Casinos Co-CEO Peter Hoetzinger said the company is considering selling its Canadian properties and its majority stake in Casinos Poland. Alberta assets could be sold as one package or split into commercial casinos and racinos. Century reported Q2 net operating revenue of $152m, adjusted EBITDAR $31.7m, and a $10.9m shareholder net loss. The review aims to reduce debt and improve value.

$CNTYMed

Century Casinos, Inc. Q2 2026 Earnings Call Summary

Century Casinos, Inc. reported Q2 2026 all-time record revenue and EBITDA, citing a 12% EBITDA rise in North America, now about 90% of total results. Management attributed gains to recent capital investment “contribution phase,” with strong Nugget and Missouri performance. It expects net debt-to-EBITDA below 6x by year-end 2026, supported by lower CapEx and cash flow, while noting Poland and Alberta risks.

$CNTYMedAI 8/10

Century Casinos, Inc. Announces Second Quarter 2026 Results

Century Casinos, Inc. (Nasdaq: CNTY) reported Q2 2026 results for the three and six months ended June 30, 2026. Net operating revenue rose 1% to $152.0 million, and earnings from operations rose 4% to $17.2 million. Adjusted EBITDAR increased 5% to $31.7 million. Cash was $60.2 million and outstanding debt $336.5 million as of June 30, 2026.

$CNTYMed

Why is Century Casinos stock climbing today?

Century Casinos (CNTY) shares rose about 4.2% pre-open after the company reported Q2 2026 results. Net operating revenue was $152.0 million (+1% YoY), earnings from operations $17.2 million (+4%), and Adjusted EBITDAR $31.7 million (+5%). First-half revenue was $289.2 million (+3%) and Adjusted EBITDAR $56.6 million (+12%). Cash was $60.2 million versus $336.5 million debt.

$CNTYMed

Century Casinos, Inc. Announces Second Quarter 2026 Results

CENTURY CASINOS INC /CO/ (CNTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. PRESS RELEASE August 7, 2026 Century Casinos, Inc. Announces Second Quarter 202 6 Results All-Time Record Q2 Net Operating Revenue and Adjusted EBITDAR, Driven by Strong Performance in North America.  Colorado Springs, Colorado – August 7, 2026 – Century Casinos, Inc. (the “Comp